Fortress Biotech Crescita futura

Criteri Future verificati 2/6

Si prevede che gli utili di Fortress Biotech diminuiranno del 101.4% all'anno, mentre si prevede che il fatturato annuo crescerà del 39.6% all'anno. Si prevede che l'EPS diminuirà del 100.4% all'anno.

Informazioni chiave

-101.4%

Tasso di crescita degli utili

-100.43%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	23.1%
Tasso di crescita dei ricavi	39.6%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	19 Nov 2025

Aggiornamenti recenti sulla crescita futura

Recent updates

Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump

Dec 16

Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

Oct 05

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks

Aug 17

FDA Approval Will Open $1 Billion Dermatology Market

Jul 06 Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.

Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Mar 11

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Oct 29

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:FBIO - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	145	-82	N/A	N/A	1
12/31/2026	110	-63	N/A	N/A	2
12/31/2025	66	-3	N/A	N/A	1
9/30/2025	62	-5	-81	-66	N/A
6/30/2025	59	-24	-95	-80	N/A
3/31/2025	58	-51	-89	-74	N/A
12/31/2024	58	-56	-95	-80	N/A
9/30/2024	82	-58	-102	-102	N/A
6/30/2024	83	-49	-100	-99	N/A
3/31/2024	85	-63	-113	-110	N/A
12/31/2023	85	-69	-136	-128	N/A
9/30/2023	62	-86	-150	-141	N/A
6/30/2023	63	-104	-176	-168	N/A
3/31/2023	64	-100	-182	-176	N/A
12/31/2022	76	-95	-202	-179	N/A
9/30/2022	78	-97	-196	-170	N/A
6/30/2022	82	-93	-181	-149	N/A
3/31/2022	81	-74	-179	-142	N/A
12/31/2021	69	-65	-133	-117	N/A
9/30/2021	64	-38	-113	-98	N/A
6/30/2021	53	-33	-110	-101	N/A
3/31/2021	44	-43	-89	-83	N/A
12/31/2020	46	-47	-91	-84	N/A
9/30/2020	43	-57	-99	-88	N/A
6/30/2020	43	-54	-92	-81	N/A
3/31/2020	43	-54	-102	-92	N/A
12/31/2019	37	-40	-104	-95	N/A
9/30/2019	34	-45	-98	-92	N/A
6/30/2019	30	-51	N/A	-101	N/A
3/31/2019	27	-53	N/A	-96	N/A
12/31/2018	27	-73	N/A	-99	N/A
9/30/2018	-107	-61	N/A	-98	N/A
6/30/2018	-65	-69	N/A	-98	N/A
3/31/2018	-22	-72	N/A	-98	N/A
12/31/2017	17	-65	N/A	-81	N/A
9/30/2017	155	-74	N/A	-78	N/A
6/30/2017	109	-60	N/A	-62	N/A
3/31/2017	61	-55	N/A	-46	N/A
12/31/2016	16	-55	N/A	-46	N/A
9/30/2016	4	-50	N/A	-35	N/A
6/30/2016	3	-55	N/A	-31	N/A
3/31/2016	1	-49	N/A	-30	N/A
12/31/2015	1	-48	N/A	-20	N/A
9/30/2015	1	-40	N/A	-17	N/A
6/30/2015	1	-27	N/A	-14	N/A
3/31/2015	1	-25	N/A	-12	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che FBIO rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che FBIO rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che FBIO rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di FBIO ( 39.6% all'anno) crescerà più rapidamente del mercato US ( 10.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di FBIO ( 39.6% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di FBIO è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/01/06 06:41
Prezzo dell'azione a fine giornata	2026/01/06 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Fortress Biotech, Inc. è coperta da 13 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Scott Henry	Alliance Global Partners
Stephen V. Byrne	BofA Global Research
Mayank Mamtani	B. Riley Securities, Inc.

Fortress Biotech Crescita futura

Criteri Future verificati 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates decrease by 11%, EPS upgraded

Price target increased by 7.5% to US$10.75

Consensus revenue estimates fall by 19%

Price target decreased by 33% to US$10.00

Price target increased by 40% to US$21.00

Consensus revenue estimates fall by 46%

Recent updates

Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump

Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission

Consensus revenue estimates decrease by 11%, EPS upgraded

Price target increased by 7.5% to US$10.75

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

New minor risk - Share price stability

Consensus revenue estimates fall by 19%

New major risk - Revenue and earnings growth

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Fortress Biotech, Inc. to Report Q2, 2025 Results on Aug 12, 2025

FDA Approval Will Open $1 Billion Dermatology Market

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 3000E Growth Index

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) completed the acquisition of Checkpoint Therapeutics, Inc. (NasdaqCM:CKPT) from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.

Price target decreased by 33% to US$10.00

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Fortress Biotech, Inc., Annual General Meeting, Jun 17, 2025

Fortress Biotech, Inc. Announces Resignation of Lucy Lu, M.D as from the Board of Directors

Price target increased by 40% to US$21.00

Consensus revenue estimates fall by 46%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Fortress Biotech, Inc. and Helocyte, Inc. Announce First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Price target increased by 7.1% to US$15.00

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Forecast to breakeven in 2026

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Consensus revenue estimates fall by 24%

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Consensus revenue estimates increase by 41%

Second quarter 2024 earnings: EPS exceeds analyst expectations

Price target increased by 7.7% to US$14.00

New minor risk - Share price stability

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations